Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Takeda Pharmaceutical Company Limited American Depositary Shares (each (NY:TAK)

18.14 +0.34 (+1.88%)
Delayed Quote Updated: 12:25 PM EDT, Oct 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Takeda Pharmaceutical Company Limited American Depositary Shares (each

< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
News headline image
5 Best High-Yield Dividend Stocks to Buy Now ↗
These five dividend stocks yield between 3.5% and 7.1%, but more importantly, they have the cash flows and business models to keep paying through the next downturn. 
Via The Motley Fool
News headline image
Takeda and VELA to Ship Medicines Across the Atlantic Using First-of-its-Kind Wind-Powered Trimaran
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda Appoints Rhonda Pacheco President of the U.S. Business Unit
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Earnings Scheduled For July 30, 2025 ↗
 
Via Benzinga
News headline image
Insights Ahead: Takeda Pharmaceutical's Quarterly Earnings ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 8, 2025 ↗
 
Via Benzinga
News headline image
Takeda Presents Orexin Data from Landmark Oveporexton (TAK-861) Phase 3 Program in Narcolepsy Type 1 at World Sleep 2025
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
U.S. FDA Approves Expanded Indication for VONVENDI® [von Willebrand factor (Recombinant)] for Adults and Children with Von Willebrand Disease
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
What's Going On With Takeda Stock On Friday? ↗
Takeda stock steadies after early dip as FDA clears Ionis' Dawnzera for hereditary angioedema, posing fresh competition to Takeda's Takhzyro. 
Via Benzinga
News headline image
Ionis Pharma Wins FDA Nod For First RNA-Targeted Therapy For Rare Genetic Swelling Disorder ↗
FDA approved Ionis' Dawnzera for hereditary angioedema, showing up to 87% attack reduction and strong results in switch patients. 
Via Benzinga
News headline image
Takeda Pharma Maintains Outlook Even As Vyvanse Generics Hit Sales ↗
Takeda reported a 30% rise in Q1 profit and beat EPS estimates, offsetting Vyvanse losses with growth in oncology, plasma, and rare disease drugs. 
Via Benzinga
News headline image
Takeda Announces First-Quarter FY2025 Results With Significant Late-Stage Pipeline Progression
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Alkermes Offers The Next Proof Point For Its Narcolepsy Approach. Stock Dives. ↗
All four companies are testing out orexin agonists to improve the symptoms of narcolpesy. 
Via Investor's Business Daily
News headline image
Takeda Receives FDA 510(k) Clearance for HyHubTM and HyHubTM Duo Devices to Simplify HYQVIA® Administration
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda Announces Positive Results from Two Pivotal Phase 3 Studies of Oveporexton (TAK-861) in Narcolepsy Type 1
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda Announces U.S. FDA Approval of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda Announces New Assignments of Directors
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Newly Diagnosed Stage IIb/III/IV Hodgkin Lymphoma in Combination with ECADD
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda and Nature Announce Call for Applications Now Open for 2026 Innovators in Science Award
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 1
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
S&P 500, Dow Jones Pharma Stocks Boomerang As Trump Threatens Drug-Price Reform ↗
It's still unclear how President Donald Trump plans to tie drug prices in the U.S. to international prices. 
Via Investor's Business Daily
Topics Government Stocks
News headline image
Japanese Pharma Company Takeda Expects Limited Exposure To US-China Tariffs ↗
Takeda reported a 25% drop in FY2024 net profit but saw revenue and operating profit growth. 
Via Benzinga
News headline image
Takeda Announces FY2024 Full Year Results and FY2025 Outlook Reflecting Growth & Launch Products Momentum, Strong Cash Flow Generation and Late-Stage Pipeline Progress
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
BioLife Plasma Services Introduces the New Fresenius Kabi Adaptive Nomogram Across its U.S. Network of Plasma Donation Centers
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda Awards $13.8 Million to U.S. Nonprofit Partners to Promote Healthy Eating and Expand STEM Education
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
UK's Health Agency Endorses Pfizer's Blood Cancer Combo Therapy As First For Untreated Hodgkin Lymphoma Patients ↗
NICE recommended Pfizer's Adcetris for NHS use in advanced Hodgkin lymphoma, citing strong trial data and a new discount agreement with Takeda. 
Via Benzinga
News headline image
Chinese Biotech Ascentage Pharma's Valuation Driven By Late-Stage De-Risked Assets: JPMorgan ↗
JP Morgan sees strong growth for Ascentage Pharma, citing its late-stage cancer drugs. The biotech's 2024 sales surged 342% YoY, driven by a Takeda payment. 
Via Benzinga
News headline image
Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed ↗
UK pharma leaders warn excessive NHS levies threaten industry growth, urging the government to reform payments. The ABPI highlights declining UK R&D investment and falling global competitiveness. 
Via Benzinga
News headline image
Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer ↗
Rusfertide met all primary and secondary endpoints in a Phase 3 trial for polycythemia vera, with strong efficacy and safety results, earning Protagonist $25 million. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.